CLDX


Insider Buying News: Cytori Therapeutics Inc (CYTX), Celldex Therapeutics, Inc. (CLDX), Nuance Communications Inc. (NUAN), Amgen, Inc. (AMGN)

Recently, various executives have taken part in insider buying activity for the stocks of Cytori Therapeutics Inc (NASDAQ:CYTX), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Nuance Communications Inc.

Insider Trading News: Skyworks Solutions Inc (SWKS), Palo Alto Networks Inc (PANW), Celldex Therapeutics, Inc. (CLDX), Rockwell Medical Inc (RMTI)

Recently, various executives have taken part in insider trading activity for the stocks of Skyworks Solutions Inc (NASDAQ:SWKS), Palo Alto Networks Inc (NYSE:PANW), Celldex Therapeutics, …

Celldex Therapeutics, Inc. Price Target Downgraded At Brean Capital Following FDA Submission Delay

In a research report released yesterday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), and reduced …

Here’s Why Cantor Reduced Price Target For Celldex Therapeutics, Inc.

In a research report released earlier today, Cantor analyst Mara Goldstein maintained a Buy rating on shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX), but reduced the …

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Reports 2Q:15 Results

Celldex Therapeutics, Inc. (NASDAQ:CLDX) reported business and financial highlights for the second quarter ended June 30, 2015.

Stock Update (NASDAQ:CLDX): Celldex Therapeutics, Inc. Appoints Richard Wright as Chief Commercial Officer

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced the promotion of Richard Wright, Ph.

Oppenheimer Maintains Outperform on Celldex Therapeutics, Inc. Following DSMN Recommendation to Continue P3 Trial of RINTEGA + SOC temzolomide

Oppenheimer analyst Christopher Marai offered some of his opinions on Celldex Therapeutics, Inc. (NASDAQ:CLDX) following a DSMB recommendation to continue the ongoing P3 trial (ACT-IV) …

Company Update (NASDAQ:CLDX): Independent Data Safety and Monitoring Board Recommends Continuation of Celldex Therapeutics, Inc.’s Phase 3 Study of RINTEGA(R)

Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that an independent Data Safety and Monitoring Board (DSMB) recommended continuation of the Phase 3 ACT IV study …

WBB Securities Raises Price Target for Celldex Therapeutics, Inc. Following Positive Phase II Results for Glioblastoma Vaccine Rintega

Celldex Therapeutics, Inc. (NASDAQ:CLDX) price target has been raised by research analyst Stephen Brozak at WBB Securities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts